Insulet Co. (PODD) Given Average Rating of “Buy” by Analysts

Share on StockTwits

Insulet Co. (NASDAQ:PODD) has been given an average recommendation of “Buy” by the thirteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $101.30.

A number of research analysts have recently issued reports on the company. BidaskClub cut Insulet from a “buy” rating to a “hold” rating in a research note on Thursday. Northland Securities reiterated a “buy” rating and set a $100.00 price target on shares of Insulet in a report on Tuesday, February 26th. Canaccord Genuity upped their target price on shares of Insulet from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, February 19th. Morgan Stanley dropped their target price on shares of Insulet from $105.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 2nd. Finally, ValuEngine cut shares of Insulet from a “strong-buy” rating to a “buy” rating in a research report on Monday, January 7th.

In other Insulet news, Director John A. Fallon sold 5,000 shares of Insulet stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $100.00, for a total transaction of $500,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP David Colleran sold 4,826 shares of Insulet stock in a transaction dated Thursday, January 31st. The shares were sold at an average price of $80.00, for a total transaction of $386,080.00. The disclosure for this sale can be found here. Insiders have sold 91,964 shares of company stock worth $8,526,720 over the last ninety days. 3.60% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP raised its stake in shares of Insulet by 3.7% during the third quarter. Dimensional Fund Advisors LP now owns 115,077 shares of the medical instruments supplier’s stock valued at $12,192,000 after purchasing an additional 4,111 shares in the last quarter. Capital International Investors purchased a new position in Insulet in the 3rd quarter worth about $18,329,000. Point72 Asset Management L.P. purchased a new position in Insulet in the 3rd quarter worth about $18,163,000. Putnam Investments LLC boosted its position in Insulet by 148.2% during the 3rd quarter. Putnam Investments LLC now owns 72,526 shares of the medical instruments supplier’s stock worth $7,684,000 after acquiring an additional 43,302 shares during the period. Finally, Macquarie Group Ltd. boosted its position in Insulet by 28.9% during the 3rd quarter. Macquarie Group Ltd. now owns 48,039 shares of the medical instruments supplier’s stock worth $5,090,000 after acquiring an additional 10,771 shares during the period.

NASDAQ:PODD traded down $1.93 during midday trading on Monday, reaching $91.42. 39,181 shares of the stock traded hands, compared to its average volume of 645,944. Insulet has a 12-month low of $70.80 and a 12-month high of $108.90. The company has a quick ratio of 3.37, a current ratio of 3.99 and a debt-to-equity ratio of 2.79. The stock has a market capitalization of $5.57 billion, a price-to-earnings ratio of 1,828.40 and a beta of 1.59.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Monday, February 25th. The medical instruments supplier reported $0.16 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.10. The firm had revenue of $164.90 million for the quarter, compared to analyst estimates of $162.45 million. Insulet had a net margin of 0.58% and a return on equity of 1.73%. The business’s quarterly revenue was up 26.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.12) earnings per share. As a group, analysts expect that Insulet will post 0.23 EPS for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

See Also: Derivative

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.